Dr. John Cush RheumNow
2 years 10 months ago
Rheumatologist SURVEY Question: How often do you start a new PMR patient on 20mg or more of prednisone? Answer here>> https://t.co/beYWFwK1LX
Dr. John Cush RheumNow
2 years 10 months ago
Sustained Efficacy of Bimekizumab in PsA
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr
Dr. John Cush RheumNow
2 years 10 months ago
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/dC9Z7UgkcO https://t.co/44QEittlEX
Dr. John Cush RheumNow
2 years 10 months ago
2005 study of 364 PMR pts (age 73.4 yrs) - 284 Rx w/ steroids, predictors of relapse =higher initial CS dose & faster CS tapering. Relapse 4-fold higher when the CS tapering rate was fast (HR 4.27). Minimize initial CS dose and taper CS slowly!! https://t.co/hUpBO7fEgh https://t.co/fv9txM0BeH
Dr. John Cush RheumNow
2 years 10 months ago
Comparison of 354 527 COVID-19 infected vs 6.1 mill controls shows COVID incr risk of alopecia areata (aHR 1.12), alopecia totalis (aHR 1.74), ANCA vasculitis (aHR 2.76), Crohns (aHR), & sarcoidosis (aHR). https://t.co/enwb2taza4 https://t.co/ljY7uMPIrm
Dr. John Cush RheumNow
2 years 10 months ago
Epidemiology of idiopathic inflammatory myopathies:
- incidence 0.2 - 2 per 100,000 PYs
- prevalence 2 - 25 per 100,000
#s vary w/ age/gender & geography; BUT is still unreported in South America, Africa & Asia https://t.co/fRUNV75xQL
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on.
Dr. John Cush RheumNow
2 years 10 months ago
New download on #PMR available now!
https://t.co/esSuRBwSr0 https://t.co/7d2B2x63tF
Dr. John Cush RheumNow
2 years 10 months ago
Steroid Tapering in #PMR: What's the Gold Standard?
Dr. Anisha Dua, Chicago, discusses the gold standard tapering of glucocorticoids in polymyalgia rheumatica.
https://t.co/oXVrHuHE58 https://t.co/fHNXodtAeV
Dr. John Cush RheumNow
2 years 10 months ago
1 in 3 of our pts are on steroids; nice ARD full read review of important papers on steroids 2022-23 written by Prof J Bijlsma, covering:
Mechanisms of action
CV AE
Bone Effects
Infections, COVID-19
Clin trials
Benefit vs Harm
Tapering
GC Guidelines
https://t.co/LnqLk8eKgn https://t.co/5xfvic5YIX
Dr. John Cush RheumNow
2 years 10 months ago
Pneumothorax in an RA patient is likely from rheumatoid nodules eroding into air spaces in advanced seropositive RA patients. https://t.co/u9rQlKKNKd https://t.co/QKquUngAld https://t.co/e9B3Jx92BW
Dr. John Cush RheumNow
2 years 10 months ago
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu
Dr. John Cush RheumNow
2 years 10 months ago
This Tuesday Night Rheumatology focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew.
https://t.co/swGbCcoEc9
@drmaxyates1 @richardpaconway @drdavidliew https://t.co/kZQ2wFbjt9
Dr. John Cush RheumNow
2 years 10 months ago
JAKi Safety and Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years
Now in the RheumNow poster hall: Long-term extension outcomes from SELECT-BEYOND through 5 years in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs.
https://t.co/xltJjADdHz https://t.co/sytZLayxDZ
